Lurbinectedin is a chemotherapy drug used to treat advanced solid tumors. There is limited information available on the adverse effects of combining lurbinectedin with other drugs. However, the available evidence suggests that there may be some adverse effects associated with combining lurbinectedin with other drugs.

According to DrugPatentWatch [1], there are no known drug interactions with lurbinectedin. However, this does not mean that there are no adverse effects associated with combining lurbinectedin with other drugs.

A study published in the Journal of Clinical Oncology [2] investigated the combination of lurbinectedin and doxorubicin in patients with advanced solid tumors. The study found that the combination was generally well-tolerated, but there were some adverse effects, including neutropenia (low white blood cell count), anemia (low red blood cell count), and thrombocytopenia (low platelet count). The study also found that the combination was effective in treating advanced solid tumors.

Another study published in the Journal of Thoracic Oncology [3] investigated the combination of lurbinectedin and pembrolizumab in patients with small cell lung cancer. The study found that the combination was generally well-tolerated, but there were some adverse effects, including fatigue, nausea, and diarrhea. The study also found that the combination was effective in treating small cell lung cancer.

In conclusion, there is limited information available on the adverse effects of combining lurbinectedin with other drugs. However, the available evidence suggests that there may be some adverse effects associated with combining lurbinectedin with other drugs. Patients should consult their healthcare provider before combining lurbinectedin with other drugs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/36252599/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/